menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy

Intellia scientists advance CRISPR-mediated targeted gene insertion in non-human primates Achieved normal circulating human Factor IX protein levels in non-human primates using targeted gene insertion High rate and specificity of acute myeloid leukemia cell killing progressed using genome-edited,
Read More

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update

CAMBRIDGE, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present first quarter 2019 results and operational highlights in
Read More

Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy

CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22 nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place April 29-May 2, 2019 , in Washington, D.C.
Read More

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results

Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on track for 2020 submission Engineered cell therapy platform will enable wholly owned development candidate for acute
Read More

Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors

CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed Fred Cohen , M.D., D.Phil, F.A.C.P., to its board of
Read More

Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population

– Intellia’s Right to Use Proprietary Lipid Nanoparticle Technology Extended to All Settings – Intellia Will Receive a One-time $10 Million Payment CAMBRIDGE, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing
Read More

Intellia Therapeutics to Present at November Healthcare Investor Conferences

CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in
Read More

Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments

Enhanced in vivo CRISPR/Cas9 cargo components have led to substantially increased liver editing and protein reduction in non-human primates that could materially improve its transthyretin amyloidosis and other in vivo product profiles Integration of enhanced components into its lead transthyretin
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments

CAMBRIDGE, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present third quarter 2018 results and corporate developments in
Read More

Intellia Therapeutics Names Glenn Goddard as New Chief Financial Officer

CAMBRIDGE, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has named Glenn Goddard its executive vice president and chief
Read More
RSS FEEDS
PRINT PAGE